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‘‘Wiping out malaria would join the
eradication of smallpox as one of the
greatest accomplishments in human history.
It is a goal we can achieve.’’
Melinda Gates, co-founder,
Bill & Melinda Gates Foundation
With more than 1 million child deaths
annually, malaria remains the single
leading killer of young children in sub-
Saharan Africa [1]. Millions more young
children survive, but still suffer from severe
anemia and permanent neurological dam-
age [1], as well as more subtle neuropsy-
chiatric disturbances including impaired
cognition and memory [2]. Malaria in
pregnancy is also a major cause of
maternal deaths and low birth weight
[3], and together these maternal and child
health effects account for huge economic
losses that trap families in poverty [4]. As a
result, malaria is now considered one of
the key forces preventing the development
of the African continent [4]. In response to
a growing malaria crisis, the Bill &
Melinda Gates Foundation recently an-
nounced an ambitious program of ex-
panded malaria control, with a long-term
goal of malaria eradication [5]. The major
elements of expanded malaria control
include strengthening of prevention and
treatment programs worldwide through
the Global Fund to Fight AIDS, Tuber-
culosis and Malaria, the United States
President’s Malaria Initiative, the World
Bank Malaria Control Booster Program,
scale-up of national control programs [5],
coordination through the Roll Back Ma-
laria Partnership based at the World
Health Organization (WHO) [6], and
advocacy by Malaria No More and other
organizations [7].
In the early 1970s, an intensified effort
to interrupt the transmission of malaria
was conducted in a group of villages near
the town of Garki in northern Nigeria [8].
Through household spraying, mass drug
administration, and other measures, there
was a temporary reduction in malaria
deaths, but overall the Garki Project
showed that interrupting malaria trans-
mission was not possible even when a full
armamentarium of control tools was
applied [8]. An important difference
between then and now is the availability
of long-lasting insecticide-treated nets
(LLITNs) and artemisinin combination
therapy (ACT)-based treatments, in addi-
tion to the increased willingness to deploy
indoor insecticide spraying [1]. However,
it is unclear whether even the deployment
of these new control tools will directly lead
to total success in malaria control because
of the threat of emerging insecticide
resistance to pyrethroids and the potential
for emergence of artemisinin resistance
[1,9,10]. Also, parallel efforts will be
required to strengthen Africa’s weakened
health systems [11,12], which today suffer
from widespread malaria misdiagnoses in
endemic areas [13] and a lack of access to
essential medicines and LLITNs [14].
Accordingly, WHO and other organiza-
tions are embarking on renewed efforts to
strengthen health systems in Africa and
elsewhere [15], while product develop-
ment partnerships have evolved in a
concerted push to accelerate the develop-
ment of additional new malaria drugs and
insecticides, and safe and effective anti-
malaria vaccines [1,5,16].
There is yet another promising, low-cost
and highly cost-effective, and complemen-
tary approach for potentially reducing the
morbidity of malaria in sub-Saharan
Africa, which builds on existing efforts
and could be implemented for as little as
US$0.50 per person per year or less than
10% add-on to projected malaria control
costs [17–20]. In sub-Saharan Africa,
where more than 90% of malaria deaths
occur, children and pregnant women are
simultaneously infected with both malaria
and a group of other parasitic diseases,
known as the neglected tropical diseases
(NTDs). The major NTDs in sub-Saharan
Africa include hookworm infection
(198 million cases) and other soil-transmit-
ted helminth infections such as ascariasis
and trichuriasis (173 million and 162 mil-
lion cases, respectively), schistosomiasis
(166 million), trachoma (33 million), lym-
phatic filariasis (46 million), and oncho-
cerciasis (18–37 million) [17,18]. There is
evidence that some of these NTDs exert
an adverse influence on the clinical
outcome of malaria in childhood and in
pregnancy [21–24], and even possibly on
malaria transmission [25]. Shown in
Figure 1 is a previously published map
demonstrating the geographic overlap and
co-endemicity of falciparum malaria and
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hookworm infection (Africa’s most com-
mon NTD), based on statistical and spatial
analyses [22]. This analysis shows high
spatial congruence of these two infections,
with one quarter of all sub-Saharan
African schoolchildren simultaneously at
risk for hookworm and malaria. Almost all
of the estimated 50 million schoolchildren
in sub-Saharan Africa with hookworm
infection are also at high risk for malaria,
except in a small band of the Sahel where
the climate is presumably too dry to
support the larval development of hook-
worms [22]. A similar association has also
been noted between malaria and schisto-
somiasis [21]. Therefore, early evidence
points to high rates of malaria and NTD
coinfections in sub-Saharan Africa, espe-
cially with hookworm infection and schis-
tosomiasis.
In Africa and other tropical developing
countries, the great killer and disabler that
results from malaria and NTD coinfections
is anemia [23,26–28]. Anemia accounts for
up to one half of malaria deaths in young
children [26], and is a leading contributor
to the huge numbers of maternal deaths
that result during pregnancy, as well as
premature births [27]. Chronic anemia in
young children is also associated with
reductions in physical growth, and im-
paired cognition and school performance
[23,24]. Many of the NTDs, but especially
two of the most common ones in sub-
Saharan Africa, hookworm infection and
schistosomiasis, cause anemia [24,28–32],
while in Asia (and presumably elsewhere),
hookworm infection, schistosomiasis, and
trichuriasis result in a synergistic anemia
[33]. Malaria also causes severe anemia
[26,27], and in cases of malaria and NTD
coinfection, anemia in vulnerable children
and women develops through one or more
of several mechanisms including blood loss,
hemolysis, anemia of inflammation, and
splenic sequestration [22–24,28–32]. An
important consequence of malaria and
NTD coinfections is an enhancement in
anemia, or what we have called previously
‘‘the perfect storm of anemia’’ [24]. For
instance, in Kenya, hemoglobin concentra-
tions were found to be 4.2 g/l lower among
children harboring hookworm and malaria
coinfections than in children with single-
species infections [23]. Because hookworm
and schistosomiasis are widespread in
Africa [17,21,22], it is likely that these
NTDs represent important contributors to
the overall mortality from childhood ma-
laria in this region [23,24,28].
Figure 1. Distribution of Hookworm and Malaria Coinfection. Geographic overlap of moderate-high hookworm infection prevalence (greater
than 20% prevalence of infection among school-aged children) and transmission of falciparum malaria transmission (based on a map of climactic
suitability for Plasmodium falciparum malaria transmission, adjusted for urbanization). Modified from [22].
doi:10.1371/journal.pntd.0000270.g001
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Similarly, most of the 7.5 million preg-
nant women infected with hookworm
likely live in areas of sub-Saharan Africa
that place them at risk for malaria [27,31].
At the same time, malaria control and
NTD control have each been shown to
reduce anemia both in children
[23,26,34,35] and in pregnant women
[30,31,36,37]. Therefore, combining ma-
laria and NTD control practices in a
unified anemia framework affords one of
the best opportunities to reduce the huge
burden of morbidity and mortality that
results from anemia in sub-Saharan
Africa. In addition to the health improve-
ment that would result from anemia
reduction, there is also some evidence that
hookworm and schistosomiasis (and possi-
bly other NTDs) may immunomodulate
their human host and promote increased
susceptibility to malaria, so that NTD
control would work in synergy with nets
and other measures to reduce malaria
incidence [25].
In sub-Saharan Africa, there are several
opportunities to link malaria and NTD
control programs [23]. They include pro-
grams targeted for infants, preschool chil-
dren, or school-aged children that employ
intermittent preventive treatment (IPT), in
which use of either sulfadoxine–pyrimeth-
amine or ACT [38] would be supplemented
with anthelminthic drugs (‘‘deworming’’) or
with a rapid-impact package of NTD drugs
that simultaneously target hookworm and
other soil-transmitted helminth infections,
lymphatic filariasis, onchocerciasis, and tra-
choma [17,23,24]. A joint program of
malaria and NTD control could be incor-
porated as a new element of Integrated
Management of Childhood Illness and other
programs for children [39]. There are also
opportunities for linking IPT in pregnancy
with anthelminthic drugs (or the rapid-
impact package) for NTD control, especially
given the benefit of deworming in terms of
improving birth outcome and reducing
maternal morbidity and mortality [36,37].
The anthelminthic drugs mebendazole and
albendazole can be used in the second and
third trimester of pregnancy and are recom-
mended byWHO in the appropriate settings
[40]. Community-based prevention efforts
could also be integrated. Both untreated
bed-nets and LLITNs are proportionately
more effective in preventing lymphatic
filariasis compared with malaria [41], and
the use of bed-nets was shown to increase
substantially, in some cases 9-fold, when
used alongside NTD control efforts [42].
Together, malaria and the seven most
common NTDs listed above cause almost
2 million deaths and are responsible for the
loss of almost 100 million disability-adjust-
ed life years (DALYs) annually (almost 20%
higher than the disease burden from HIV/
AIDS) [23]. Much of this high disease
burden operates through the mechanism of
anemia. According to J. Crawley, ‘‘…an
integrated and non-disease specific ap-
proach is essential if the intolerable burden
of anemia that currently exists in malaria-
endemic regions of Africa is going to be
reduced’’ [43]. Although there will be
operational challenges to integrating NTD
with malaria control, the opportunities for
improving health, education, and economic
development for the poorest people in sub-
Saharan Africa are simply too great for us
to ignore. Accordingly, the public–private
partnerships of the Global Network for
NTDs are working to identify opportunities
for integration [18]. In addition, given the
ability of hookworm and other NTDs to
interfere with vaccine immunogenicity, we
also need to consider the importance of
NTD research for the malaria research
agenda [44], as well as the opportunity to
develop new NTD drugs and vaccines
alongside new innovations in malaria
treatment and prevention [45].
It is likely that focusing control efforts
on malaria alone will thwart global efforts
to sustain malaria control, much less
achieve eradication. Ultimately, by reduc-
ing anemia in sub-Saharan Africa, linking
the NTDs with malaria control would
have a major impact on almost all of the
Millennium Development Goals [20]. It is
some four years since this approach was
suggested [19], but policy makers are only
gradually recognizing the benefits of more
holistic approaches to tackling the diseases
of the poor. An integrated control pro-
gram for tropical anemia in Africa repre-
sents one of our better hopes for a quick
win in the fight for sustainable disease
control and poverty reduction.
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